A Long-Term Benefit of Darolutamide for Patients with nmCRPC
Results from the ARAMIS rollover study have been presented at this year’s ASCO-GU23. Following a primary double-blinded analysis, these findings suggest long-term clinical benefit and tolerability for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) remaining on darolutamide for ≥4 years.
